NPI: 1457323164 · NASHVILLE, TN 37215 · Professional Counselor · NPI assigned 02/06/2006
Authorized official PINCINCE, DEBORAH controls 20+ related entities in our dataset. Read more
| Authorized Official | PINCINCE, DEBORAH (ADMINISTRATOR) |
| NPI Enumeration Date | 02/06/2006 |
Other providers sharing the same authorized official: PINCINCE, DEBORAH
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 23,429 | $751K |
| 2019 | 28,583 | $1.14M |
| 2020 | 37,185 | $835K |
| 2021 | 132,602 | $2.21M |
| 2022 | 113,645 | $1.25M |
| 2023 | 111,586 | $1.07M |
| 2024 | 99,126 | $768K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32,064 | 28,624 | $1.93M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38,390 | 34,212 | $1.57M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 43,881 | 36,038 | $1.30M |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 13,561 | 12,304 | $802K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 54,911 | 48,508 | $724K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 14,691 | 13,070 | $335K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 19,510 | 16,659 | $313K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5,770 | 5,087 | $290K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 6,054 | 4,591 | $249K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 16,645 | 7,422 | $146K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 11,706 | 10,448 | $106K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3,540 | 2,550 | $90K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 646 | 591 | $60K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3,054 | 2,601 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 658 | 603 | $30K |
| 90674 | 1,132 | 981 | $18K | |
| 90686 | 723 | 642 | $10K | |
| 99401 | 185 | 172 | $4K | |
| 86580 | 892 | 785 | $4K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 55 | 52 | $4K |
| 81002 | 2,652 | 2,244 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 218 | 173 | $3K |
| 99201 | 103 | 94 | $3K | |
| 90661 | 85 | 59 | $2K | |
| 0081A | 29 | 15 | $1K | |
| 3079F | 4,508 | 3,917 | $670.21 | |
| 3074F | 50,417 | 44,734 | $612.40 | |
| 3077F | 648 | 559 | $588.19 | |
| 0031A | 25 | 13 | $485.88 | |
| 90682 | 14 | 13 | $484.00 | |
| 3078F | 40,569 | 36,115 | $453.02 | |
| 81025 | 169 | 148 | $423.06 | |
| 3075F | 1,516 | 1,336 | $420.85 | |
| 3080F | 358 | 312 | $268.20 | |
| 36415 | Collection of venous blood by venipuncture | 224 | 206 | $195.82 |
| 3008F | 52,384 | 46,116 | $27.00 | |
| 1159F | 37,248 | 32,848 | $25.02 | |
| 1160F | 34,719 | 30,648 | $25.02 | |
| 1036F | 51,628 | 45,131 | $8.02 | |
| 4124F | 495 | 473 | $0.00 | |
| 4120F | 79 | 77 | $0.00 |